Provention Bio Inc

Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn’s disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Provention Bio is a clinical-stage biopharmaceutical company dedicated to sourcing, developing, and commercializing novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated disease. Their predict and prevent model is focused on developing novel therapeutic approaches that intervene before the target disease begins, re-appears, or progresses.  Provention Bio offers the potential to reduce the high morbidity, mortality, patient suffering, and escalating costs of chronic autoimmune and inflammatory diseases, such as type 1 diabetes (T1D), Crohn’s disease, ulcerative colitis, and emerging viral infections. They believe Provention’s business model, coupled with its expertise in translational medicine, immunology, and the design and execution of rapid go/no-go clinical trials, will enable them to in-license and efficiently partner both early-stage development assets and more advanced clinical-stage opportunities.

Sanofi

Sanofi US to co-promote teplizumab, adding it to its current commercial activities in diabetes care, leveraging its existing best-in-class customer-facing field teams Provention Bio, Inc. retains all rights to teplizumab Commercialization activities are dependent on U.S. FDA approval of teplizumab, potentially on November 17, 2022 BRIDGEWATER, N.J. , Oct. 6, 2022 /PRNewswire/ -- Sanofi US has announced it has entered into a co-promotion service agreement with Provention Bio, Inc., for the commercialization of teplizumab in the United States.

Sanofi US enters into co-promotion agreement with Provention Bio, Inc. to launch teplizumab, an investigational disease-modifying therapy for type 1 diabetes

Provention receives $20 million nonrefundable payment granting Sanofi exclusive right of first negotiation to in-license teplizumab globally for T1D U.S. copromotion agreement leverages Sanofi's in-market infrastructure and established expertise in endocrinology to expand reach, increase awareness and drive T1D screening Sanofi to invest $35 million at a premium after a potential teplizumab FDA approval Investor Conference call at 8:30am ET Today RED BANK, N.J. , Oct. 6, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company has entered into a co-promotion agreement with Sanofi U.S. for the launch of Provention's lead investigational drug candidate teplizumab.

Provention Bio to Combine Forces with Sanofi to Support Potential U.S. Launch of Teplizumab for Delay in Onset of Clinical Type 1 Diabetes (T1D) in At-Risk Individuals

It could be a make-or-break end of the year for the company.

1 Green Flag and 1 Red Flag for Provention Bio

RED BANK, N.J. , Sept. 19, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company has appointed Sarah O'Brien as Chief People Officer.

Provention Bio Announces Senior Leadership Addition

RED BANK, N.J. , Sept. 6, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will participate virtually in a corporate presentation at the H.C.

Provention Bio to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Hercules Capital

RED BANK, N.J. , Aug. 31, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company has secured a term loan facility of up to $125 million with Hercules Capital, Inc. (NYSE: HTGC), a leader in customized financing for companies in life sciences.

Provention Bio Announces $125 Million Term Loan Facility with Hercules Capital

Provention Bio, Inc. (NASDAQ:PRVB ) Q2 2022 Earnings Conference Call August 4, 2022 8:00 AM ET Company Participants Robert Doody - Vice President, Investor Relations Thierry Chauche - Chief Financial Officer Ashleigh Palmer - Co-Founder, President, Chief Executive Officer Jason Hoitt - Chief Commercial Officer Francisco Leon - Co-Founder & Chief Scientific Officer Conference Call Participants Justin Kim - Oppenheimer Raghuram Selvaraju - H.C. Wainwright Prakhar Agrawal - Cantor Fitzgerald Thomas Smith - SVB Securities David Hoang - SMBC Nikko Operator Good morning.

Provention Bio, Inc. (PRVB) CEO Ashleigh Palmer on Q2 2022 Results - Earnings Call Transcript

Provention Bio, Inc. (PRVB) delivered earnings and revenue surprises of 6.12% and 6.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Provention Bio, Inc. (PRVB) Reports Q2 Loss, Lags Revenue Estimates

-Teplizumab Biologics License Application (BLA) user fee goal date extended to November 17, 2022- -Company completes $60.0 million private placement- RED BANK, N.J. , Aug. 4, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today reported financial results for the second quarter ended June 30, 2022, and provided a business update.

Provention Bio Reports Second Quarter 2022 Financial Results and Provides Business Update

RED BANK, N.J. , July 28, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it will report its second quarter 2022 financial results on Thursday, August 4, 2022, before the opening of the U.S. financial markets.

Provention Bio to Report Second Quarter 2022 Financial Results on August 4, 2022

Are the Street's predictions too optimistic?

This Stock Could Soar by Nearly 300%, Says Wall Street

RED BANK, N.J. , July 7, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced it has entered into a securities purchase agreement with institutional investors for the private placement of approximately $60 million of shares of its common stock and warrants to acquire 13,318,535 additional shares of its common stock (the "Warrants") (collectively, the "Securities").

Provention Bio Announces $60 Million Private Placement

RED BANK, N.J. , June 30, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended its review period by three months for the Biologics License Application (BLA) for teplizumab.

Provention Bio Announces Extension of FDA User Fee Goal Date for Teplizumab to November 17, 2022

RED BANK, N.J. , June 3, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will participate in a corporate presentation at the Jefferies Global Healthcare Conference on Wednesday, June 8 th 2022 at 9:00 am EST in New York City.

Provention Bio to Present at the Jefferies Global Healthcare Conference

RED BANK, N.J. , June 3, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced Dr. Jeffrey Bluestone's decision to step down as a director on the Company's board of directors to focus on his other commitments, including his role as President and Chief Executive Officer of Sonoma Biotherapeutics.

Provention Bio Announces Update to Board of Directors

bluebird bio

2 High-Risk, High-Reward Stocks for Contrarian Investors

RED BANK, N.J. , May 12, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it will host an investor event on Thursday, May 19, 2022 focused on the potential commercial launch of teplizumab in the second half of this year.

Provention Bio to Host a May 19, 2022 Virtual Investor Event Focused on the Potential Commercial Launch of Teplizumab Later This Year

Provention Bio, Inc. (NASDAQ:PRVB ) Q1 2022 Earnings Conference Call May 5, 2022 8:00 AM ET Company Participants Ashleigh Palmer – Co-Founder, President, Chief Executive Officer Francisco Leon – Co-Founder & Chief Scientific Officer Thierry Chauche – Chief Financial Officer Jason Hoitt – Chief Commercial Officer Robert Doody – Vice President, Investor Relations Conference Call Participants Gregory Renza – RBC Capital Markets Thomas Smith – SVB Leerink David Hoang – SMBC Nikko Securities America, Inc Operator Good morning. My name is Kate, and I will be your conference Operator today.

Provention Bio, Inc. (PRVB) CEO Ashleigh Palmer on Q1 2022 Results - Earnings Call Transcript

Provention Bio, Inc. (PRVB) delivered earnings and revenue surprises of 22.22% and 20.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Provention Bio, Inc. (PRVB) Reports Q1 Loss, Lags Revenue Estimates

-Teplizumab Biologics License Application (BLA) resubmission accepted for review by FDA and user fee goal date set for August 17, 2022- -Company to host teplizumab commercial launch investor event on Thursday, May 19, 2022- RED BANK, N.J. , May 5, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today reported financial results for the first quarter ended March 31, 2022, and provided a business update.

Provention Bio Reports First Quarter 2022 Financial Results and Provides Business Update

RED BANK, N.J. , April 28, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it will report its first quarter 2022 financial results on Thursday, May 5, 2022, before the opening of the U.S. financial markets.

Provention Bio to Report First Quarter 2022 Financial Results on May 5, 2022

Provention Bio Inc (NASDAQ: PRVB) announced results from the final analysis of its first-in-human PROVENT study of PRV-101, a polyvalent inactivated coxsackievirus B (CVB) vaccine candidate. Provention is developing PRV-101 for the prevention of acute CVB infection and its.

Provention Bio's Coxsackievirus Vaccine Candidate Elicits Durable Virus-Neutralizing Antibodies At Six Months

PRV-101 continued to be well tolerated and elicited durable high titers of virus-neutralizing antibodies in a dose-dependent fashion in healthy volunteers RED BANK, N.J. , March 28, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced positive results from the final analysis of its first-in-human PROVENT study of PRV-101, a polyvalent inactivated coxsackievirus B (CVB) vaccine candidate targeting all key CVB strains associated with type 1 diabetes (T1D) autoimmunity.

Provention Bio Announces Positive Final Results from First-In-Human Study of Coxsackievirus B Vaccine Candidate PRV-101

RED BANK, N.J., March 3, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will participate in two upcoming virtual investor conferences in March.

Provention Bio to Present at Two Upcoming Virtual Investor Conferences

Provention Bio, Inc's. (PRVB) CEO Ashleigh Palmer on Q4 2021 Results - Earnings Call Transcript

News for Provention Bio Inc Stock (PRVB)